Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Use of Resources Study (PURE)
2024-515542-16-03Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in end-stage kidney disease (ESKD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: LCPT dose reduction feasibility with maintained therapeutic tacrolimus levels. Started Jan 2025; status: completed.
02
Drugs
tacrolimus
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-515542-16-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515542-16-03.